Skip to main content
. Author manuscript; available in PMC: 2019 Feb 2.
Published in final edited form as: Oncogene. 2018 Aug 2;37(50):6442–6462. doi: 10.1038/s41388-018-0420-z

Figure 8: Multidimensional analysis of sdRNAs at the interface of tumor immunity and survival.

Figure 8:

a. Schematic of the ImmuneSurv score. In a cancer type-specific manner, each sdRNA is assessed for whether it is significantly associated with PD-L1 expression, CD8+ T cell abundance, GZMA expression, and patient survival. Each significant association adds 1 point to the ImmuneSurv score.

b. Left: bar plot of sdRNAs aggregated by parental snoRNA with ImmuneSurv scores ≥ 2 in at least one cancer type. Right: bar plot of the 25 parental snoRNAs with ImmuneSurv scores ≥ 2 in at least 4 cancer types. Strikingly, SCARNA4 was found to have ImmuneSurv scores ≥ 2 in 9 independent cancer types.

c. Heat map of ImmuneSurv scores for the 25 parental snoRNAs in b. Individual cells are colored based on ImmuneSurv score for the indicated snoRNA in each cancer type.

d. Venn diagram of sdRNAs significantly associated with PD-L1, CD8+ T cells, and/or GZMA in pancreatic adenocarcinoma (PAAD).

e. Venn diagram of sdRNAs significantly associated with PD-L1, CD8+ T cells, GZMA, and/or survival in lower grade glioma (LGG).

f. Venn diagram of sdRNAs significant for PD-L1 correlation, CD8+ T cell abundance, GZMA correlation, patient survival, and/or copy number variation in any cancer type (PANCAN32).